TiGenix

Canaccord Genuity is pleased to announce that on March 14, 2016, it completed a private placement for TiGenix NV of €23.75 million in gross proceeds through a private placement of 25,000,000 new shares (the “New Shares”) at a subscription price of €0.95 per share. The New Shares represent 12.4% of the total number of 202,304,587 shares outstanding after the issue of the New Shares which are expected to be admitted to trading on Euronext Brussels following their issuance. Canaccord Genuity acted as Placement Agent. TiGenix NV intends to use the net proceeds to advance the Cx601 marketing authorization approval process in Europe and the technology transfer of Cx601 to Lonza, a U.S.- based contract manufacturer, to enable the launch of the future phase III study of Cx601 in the U.S.

In addition, Canaccord Genuity is also acting as Left Bookrunner for the F1 NASDAQ IPO currently on file.

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programs. The stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory and heart diseases. The Company is expecting European approval for its lead product candidate in the treatment of complex perianal fistulas in patients suffering from Crohn's disease in 2017, and expects to initiate a U.S. Phase III trial in H2 2016.